Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Recommendation of “Hold” by Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have received an average recommendation of “Hold” from the twenty-two ratings firms that are covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell rating, ten have given a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $106.20.

A number of research analysts recently weighed in on the company. UBS Group reissued a “sell” rating and issued a $89.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their target price for the stock from $94.00 to $120.00 in a research report on Monday, January 5th. The Goldman Sachs Group downgraded Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target on the stock. in a report on Friday, January 9th. Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Citigroup restated a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several large investors have recently made changes to their positions in ZBH. Key Financial Inc boosted its stake in Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the period. DV Equities LLC bought a new position in Zimmer Biomet in the 4th quarter worth approximately $25,000. Cullen Frost Bankers Inc. lifted its holdings in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 116 shares during the last quarter. Root Financial Partners LLC bought a new stake in shares of Zimmer Biomet in the third quarter valued at approximately $31,000. Finally, Cary Street Partners Investment Advisory LLC boosted its position in shares of Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 149 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.1%

Shares of NYSE:ZBH opened at $88.52 on Tuesday. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $17.32 billion, a PE ratio of 25.01, a P/E/G ratio of 1.81 and a beta of 0.58. Zimmer Biomet has a 1 year low of $84.59 and a 1 year high of $114.44. The firm has a fifty day moving average price of $92.02 and a 200 day moving average price of $93.90.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. During the same period last year, the company earned $2.31 earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts expect that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s payout ratio is currently 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.